Targeted NGS insights with liquid biopsy

Liquid Biopsy – A transformative tool for clinical oncology research  

Liquid biopsy testing refers to the non-invasive analysis of tumor-derived genomic material found in the blood or other biofluids, such as bile, cerebro-spinal fluid, or urine.

Liquid biopsies offer several advantages and can deliver a relevant genomic profile even if a tissue sample is unavailable, or complement tissue samples to understand tumor heterogeneity. 

Oncomine Liquid Biopsy Solutions for
Clinical Oncology Research

We offer a range of Oncomine cfNA liquid biopsy assays for applications across a spectrum of disease research areas.

Each assay enables relevant insights into the genomic makeup of tumors and is provided as part of a complete solution on 2 amplicon-based next-generation sequencing (NGS) platforms, the Ion GeneStudio^TM S5 System and the Ion Torrent^TM Genexus System^TM.

Integrated analysis software enhances the efficiency of reporting and the interpretation of your NGS results.

The highly automated workflow helps simplify the testing process, allowing minimal hands-on time and making NGS testing accessible to laboratories of almost all levels of experience and expertise.

Multi-biomarker DNA and RNA insights in 1 to 3 days
from a single tube of blood

Simultaneous analysis of cfDNA (relevant SNVs, indels and CNVs) and cfRNA (fusions to test for all relevant biomarkers)

Reliable results from multiple sample sources: Such as ctNA from blood, bile, cerebrospinal fluid, and urine

Low sample input requirements of as little as 1 ng of total cell-free nucleic acid and high sensitivity with 0.1% LOD to detect even low-level variants

End-to-end highly automated workflow with as little as 20 min hands on time (HOT) to help reduce complexity of implementation and maintenance, needs for bioinformatics expertise and potentially save your technicians' time

Turnaround Time (TAT) of 1-3 days to enable you to deliver relevant reports with speed  

The Oncomine cfNA Assay Portfolio

Multi-cancer and tumor-type specific gene coverage to fit your lab’s needs.

Oncomine Breast cfDNA Assay v2

Oncomine Colon cfDNA Assay

> View Oncomine cfNA Portfolio Brochure

> View Oncomine Pan-Cancer Cell-Free Assay Flyer

Assay Portfolio Gene Content

Experiences of Oncomine cfNA assay users

Featured Customer Presentation

Oncomine Precision Assay: Automated and decentralized genomic profiling of plasma cell-free DNA

Dr. Ting Chan, PhD
Curation Scientist, Centre for Cancer Research
University of Melbourne
Melbourne, Australia

Dr. Brandon Sheffield, MD
Pathologist, W. Osler Health System,
Brampton, Ontario

“The Oncomine Precision Assay, is novel…in that it also looks at circulating cell-free tumor derived RNA to detect fusions as opposed to most of the commercially available assays, which are looking only at DNA.”

Beatriz Bellosillo, PhD
Hospital del Mar,
Spain

“Genomic heterogeneity after anti-EGFR therapy was successfully detected in 94% of the metastatic colorectal cancer research samples using a next-generation sequencing multi-biomarker approach. The Oncomine Colon cfDNA Assay enabled detection of somatic mutations with MAF >0.1%.

Additional Resources

Question?

Request to speak to a Thermo Fisher Scientific NGS expert below. We will be happy to answer all your question and provide a demo.

For Research Use Only. Not for use in diagnostic procedures.

All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified.

Case Number: 54982 0724